SCHEMBL14770520

SCHEMBL14770520

COc1ccc(C(C)c2nc3ccc(Cl)nc3[nH]2)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRS3 P32247 1/20 0.38
TUBB4A P04350 2/20 0.37
TUBB P07437 2/20 0.37
TUBA3C P0DPH7 2/20 0.37
TUBA1B P68363 2/20 0.37
TUBA4A P68366 2/20 0.37
TUBB4B P68371 2/20 0.37
TUBB3 Q13509 2/20 0.37
TUBB2A Q13885 2/20 0.37
TUBB8 Q3ZCM7 2/20 0.37
TUBA3E Q6PEY2 2/20 0.37
TUBA1A Q71U36 2/20 0.37
TUBA1C Q9BQE3 2/20 0.37
TUBB6 Q9BUF5 2/20 0.37
TUBB2B Q9BVA1 2/20 0.37
TUBB1 Q9H4B7 2/20 0.37
GAA P10253 3/20 0.36
ALDH1A1 P00352 2/20 0.36
LMNA P02545 1/20 0.36
CYP1A2 P05177 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14770513 0.85 MLKL (0.43) BRS3TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL14770519 0.78 MAPK1 (0.38) BRS3CYP1A2CYP2E1CYP3A4CYP2C8
SCHEMBL14770550 0.75 FLT3 (0.40) BRS3GAALMNACYP1A2CYP2E1
SCHEMBL14770674 0.73 SMN1; SMN2 (0.56) GAAALDH1A1PTGESALOX5LTC4S
SCHEMBL14770549 0.73 ALDH1A1 (0.42) BRS3ALDH1A1LMNACYP1A2CYP2E1
SCHEMBL14770631 0.73 GSK3A (0.36) PTGESALOX5LTC4SCOMTROCK2
SCHEMBL14770635 0.73 DYRK1B (0.38) ALDH1A1LMNARAB9ACOMTROCK2
SCHEMBL14770630 0.70 AMY1A (0.42) BRS3ALDH1A1LMNACYP1A2CYP2E1
SCHEMBL14770492 0.69 AMY1A (0.41) ALDH1A1LMNAPTGESALOX5LTC4S
SCHEMBL14770613 0.69 FLT3 (0.40) ALDH1A1LMNACYP1A2CYP2E1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9096531-B2 Fused imidazole derivative TOA EIYO LTD. (JP) 2015-08-04 US disclosed
US-20130065896-A1 FUSED IMIDAZOLE DERIVATIVE TOA EIYO LTD. (JP) 2013-03-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130065896-A1 FUSED IMIDAZOLE DERIVATIVE CACNA1E, CACNA1G, CACNA1A BRS3 445/4885TUBB4A 1309/4885TUBB 1143/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.